

U.S.S.N.: 09/768,155  
Filed: January 23, 2001  
RESPONSE

**APPENDIX: Clean Copy of Claims as Amended**

1. (amended) A method for treating a lupus patient characterized by the presence of anti-dsDNA antibodies comprising administering to the patient single chain anti-idiotypic antibody fragments immunoreactive with anti-dsDNA antibodies, wherein the antibody fragments prevent the anti-dsDNA antibodies from interfering with protein synthesis.

2. (amended) The method of claim 1 wherein the antibody fragments are derived from human antibodies.

3. (amended) The method of claim 1 wherein the antibody fragments are conjugated to a carrier molecule or is a fusion protein.

5. (amended) The method of claim 1 wherein the antibody fragment is derived from an anti-idiotypic antibody immunoreactive with anti-dsDNA antibody.

6. The method of claim 5 wherein the antibody is administered in a dosage effective to kill anti-dsDNA antibody producing cells.

7. The method of claim 5 wherein the antibody is administered in a dosage effective to decrease the amount of anti-dsDNA antibody levels in the patient.

8. (amended) A therapeutic composition in a pharmaceutically acceptable carrier for administration to a patient comprising an effective amount of single chain anti-idiotypic antibody fragments immunoreactive with anti-dsDNA antibodies, wherein the antibody fragments prevent the anti-dsDNA antibodies from interfering with protein synthesis.

U.S.S.N.: 09/768,155  
Filed: January 23, 2001  
RESPONSE

9. (amended) The composition of claim 8 wherein the antibody fragments are derived from human antibody.

10. (amended) The composition of claim 8 wherein the antibody fragments are conjugated to a carrier molecule or is a fusion protein.

12. (amended) The composition of claim 8 wherein the composition is an antibody fragment derived from an anti-idiotypic antibody immunoreactive with anti-dsDNA antibody.

13. The composition of claim 12 wherein the antibody is administered in a dosage effective to kill anti-dsDNA antibody producing cells.

14. The composition of claim 12 wherein the antibody is administered in a dosage effective to decrease the amount of anti-dsDNA antibody levels in the patient.

ATL1 #540717 v1